Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Pharm Des. 2012;18(25):3721-30.

CD36 as a therapeutic target for endothelial dysfunction in stroke.

Author information

  • 1Department of Neurology/ Neuroscience, Weill Cornell Medical College at Burke Medical Research Institute, 785 Mamaroneck Ave., White Plains, New York 10605, USA. suc2002@med.cornell.edu

Abstract

Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.

PMID:
22574985
PMCID:
PMC3411860
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
    Loading ...
    Write to the Help Desk